Hospital Pharmacy

These medication errors have occurred in health care facilities at least once. They will happen again—perhaps where you work. Through education and alertness of personnel and procedural safeguards, they can be avoided. You should consider publishing accounts of errors in your newsletters and/or presenting them in your inservice training programs.

Your assistance is required to continue this feature. The reports described here were received through the USP Medication Errors Reporting Program (MERP), which is presented in cooperation with the Institute for Safe Medication Practices. If you have encountered medication errors and would like to report them, you may call USP toll-free, 24 hours a day, at 800-233-7767 (800-23-ERROR).

Any reports published by ISMP will be anonymous. Comments are also invited; the writers' names will be published if desired. ISMP may be contacted at the address shown below.

Errors, close calls, or hazardous conditions may be reported through the ISMP (www.ismp.org) or USP (www.usp.org) Web sites or communicated directly to ISMP by calling 800-FAIL-SAFE or via E-mail at ismpinfo@ismp.org. ISMP guarantees the confidentiality and security of the information received and respects reporters' wishes as to the level of detail included in publications.

The purpose of this feature is to heighten awareness of specific adverse drug reactions (ADRs), discuss methods of prevention, and promote reporting of ADRs to the FDA's medWatch program (800-FDA-1088). If you have reported an interesting preventable ADR to medWatch, please consider sharing the account with our readers.

The increasing complexity of cancer chemotherapy heightens the requirement that pharmacists be familiar with these highly toxic agents. This column will review various issues related to preparation, dispensing, and administration of cancer chemotherapy. It will also serve as a review of various agents, both commercially available and investigational, used to treat malignant diseases.

Off-Label Drug Uses — This Hospital Pharmacy feature is extracted from Off-Label DrugFacts, a quarterly publication available from Wolters Kluwer Health. Off-Label DrugFacts is a practitioner-oriented resource for information about specific FDA-unapproved drug uses. This new guide to the literature will enable the health care professional/clinician to quickly identify published studies on off-label uses and to determine if a specific use is rational in a patient care scenario. The most relevant data are provided in tabular form, so the reader can easily identify the scope of information available. A summary of the data—including background, study design, patient population, dosage information, therapy duration, results, safety, and therapeutic considerations—precedes each table of published studies. References direct the reader to the full literature for more comprehensive information prior to patient care decisions. Direct questions or comments regarding “Off-Label Drug Uses” to hospital pharmacy@drugfacts.com.

A number of technological advances are becoming incorporated into institutional pharmacy practice in order to reduce the frequency and severity of medication errors. One of these has great promise. They deal with intravenous (IV) medication safety systems, wherein customized drug software is interfaced with “intelligent” infusion pumps. This paper describes the implementation and initial evaluation of Hospira's MedNet decision support infusion software in a five-hospital health care system in Pennsylvania. All of the steps are reviewed (identification of stakeholders, evaluation of software capabilities, evaluation of institution-specific practices, decisions regarding standard operating procedures, writing of the drug libraries, and preparation for “going live”) in detail. In addition, the initial results of the system are described, especially with respect to potential medication errors avoided. The well-documented medication error avoidance potential of such systems has proven useful in a clinical setting.

Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. With a subscription, the monographs are sent to you in print and CD ROM forms and are available online. Monographs can be customized to meet the needs of your facility. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X.

Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The February 2006 monograph topics are fentanyl (hydrochloride) patient-activated transdermal system, sipuleucel-T artificial embolization device, anecortave acetate for depot suspension, and dextromethorphan/quinidine sulfate. The DUE is on fentanyl (hydrochloride) patient-activated transdermal system.

This monthly feature will help readers keep current on new drugs, indications, dosage forms, and safety-related changes in labeling or use. Each month, new information will be added to the table (shown in bold type) and older information will be removed. Efforts have been made to ensure the accuracy of the information; however, if there are any questions, let us know at hospitalpharmacy@drugfacts.com.

The next several Director's Forum articles will focus on core practices or competencies in hospital pharmacy practice. This series of articles will discuss the key fundamentals, resources, challenges, and opportunities associated with drug dispensing. Future core competency forums will include discussions on medication ordering, intravenous admixtures, data analysis, and regulatory requirements.

In Director's Forum, we hope to answer key questions that pharmacy directors face and provide others with information to foster growth in pharmacy leadership. The articles in this column will build on one another and, when put together, will serve as a “tool kit” to develop patient-centered pharmacy services in hospitals of all sizes. Examples of topics in future Director's Forums will include establishing clinical service priorities, justifying clinical pharmacist positions, implementing a patient safety program, and budgeting for patient-centered services.

Nutrition Support Pharmacist features issues pertinent to the practice of clinical pharmacy in the area of nutritional support. The column is edited by Dr. Roland Dickerson, Professor of Pharmacy, University of Tennessee Health Science Center; Memphis, TN. Address correspondence to Dr. Roland N. Dickerson, University of Tennessee Health Science Center, 26 South Dunlap St., Memphis, TN 38163.

This article provides a summary of our approach to the nutritional management of the thermally injured patient. However, it must be pointed out that there are other alternative effective evidence-based approaches to managing this problematic patient population. There are numerous exceptions to the above outlined guidelines that the astute clinician must be able to identify. However, for the beginning reader, this approach will provide a sound foundation upon which to build their practice in the management of these difficult patients.